Comparing the current results to its competitors, Cue Biopharma Inc reported Revenue increase in the 2 quarter 2026 by 166.66 % year on year. The sales growth was above Cue Biopharma Inc 's competitors' average revenue growth of 2.19 %, achieved in the same quarter.
Cue Biopharma Inc 's Comment on Competition and Industry Peers
The company operates in the immunotherapy sector, focusing on its Immuno-STAT platform that targets disease-relevant T cells. It competes with pharmaceutical and biotechnology companies, academic institutions, governmental agencies, and research organizations developing cytokine-based therapies, monoclonal antibodies, bi-specific antibodies, cell therapies, and vaccines for autoimmune diseases. Notable competitors in cytokine-based therapies include Amgen, Bristol-Myers Squibb, Merck & Co., Nektar Therapeutics, Sanofi S.A., TRex Bio, and RegCell. In the regulatory T cell therapy area, competitors include Coya Therapeutics, Quell Therapeutics, EVOQ Therapeutics, and Sonoma Biotherapeutics. Several competitors possess greater financial, technical, and human resources, as well as more extensive product development experience.
June 4, 2024
Interim Data Shows Promise: Cue Biopharma’s CUE-101 in Advanced HPV+ Head and Neck Cancer BOSTON, June 4, 2024 Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical innovator, has announced significant, updated data from its currently progressing Phase 1 trial on CUE-101. This announcement reverberated through the halls of the American Society of Clinical Oncology (ASCO) Annual Meeting, held today in Chicago, IL, as the company delivered a comprehensive oral presentation elucidating the therapeutic potential of their lead oncology asset tailored for recurrent and metastatic HPV-positive (HPV+) head and neck cancer.Cue Biopharma s CUE-101 is part of the groundbreaking CUE-100 series of b...
Biolinerx Ltd is a biopharmaceutical company that focuses on discovering, developing, and commercializing novel therapeutics for various diseases. Their business model revolves around the research and development of innovative drug candidates, conducting clinical trials to assess their safety and efficacy, and obtaining regulatory approvals to bring these treatments to market. They aim to generate revenue through licensing agreements, strategic collaborations, and the sale of their therapeutics to patients or healthcare providers.
Iovance Biotherapeutics Inc operates on a business model centered around developing and commercializing novel cancer immunotherapy treatments. The company focuses on utilizing its proprietary Tumor Infiltrating Lymphocyte (TIL) therapy, which involves collecting and expanding a patient's own immune cells to target and kill cancer cells. Iovance primarily seeks to advance its TIL therapy candidates through clinical trials and collaborations while aiming to provide effective and personalized treatment options for cancer patients.
Kezar Life Sciences Inc is a biotechnology company that focuses on developing novel small molecule therapeutics. Their business model revolves around the discovery and development of innovative drugs to target autoimmune and inflammatory disorders, aiming to address unmet medical needs. They primarily operate by conducting extensive research and conducting clinical trials to deliver effective treatments for patients.
Sources:
Cue Biopharma Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Cue Biopharma Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
